NZ603529A - Antibodies to human gdf8 - Google Patents
Antibodies to human gdf8Info
- Publication number
- NZ603529A NZ603529A NZ603529A NZ60352911A NZ603529A NZ 603529 A NZ603529 A NZ 603529A NZ 603529 A NZ603529 A NZ 603529A NZ 60352911 A NZ60352911 A NZ 60352911A NZ 603529 A NZ603529 A NZ 603529A
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- amino acid
- gdf8
- antibody
- tgfb1
- Prior art date
Links
- 101100228739 Danio rerio mstnb gene Proteins 0.000 title 1
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 abstract 2
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 abstract 2
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000004071 biological effect Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102000054677 human MSTN Human genes 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Radiology & Medical Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34855910P | 2010-05-26 | 2010-05-26 | |
| US37288210P | 2010-08-12 | 2010-08-12 | |
| PCT/US2011/037837 WO2011150008A1 (en) | 2010-05-26 | 2011-05-25 | Antibodies to human gdf8 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ603529A true NZ603529A (en) | 2015-07-31 |
Family
ID=44477626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ603529A NZ603529A (en) | 2010-05-26 | 2011-05-25 | Antibodies to human gdf8 |
Country Status (40)
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014DN10515A (US07935481-20110503-C00024.png) | 2006-03-31 | 2015-08-21 | Chugai Pharmaceutical Co Ltd | |
| HUE029635T2 (en) | 2007-09-26 | 2017-03-28 | Chugai Pharmaceutical Co Ltd | A method for modifying an isoelectric point of an antibody by amino acid substitution in CDR |
| HUE028718T2 (en) | 2008-04-11 | 2016-12-28 | Chugai Pharmaceutical Co Ltd | An antigen-binding molecule capable of binding to two or more antigen molecules |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| EP2606066A1 (en) | 2010-08-16 | 2013-06-26 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
| RU2658504C9 (ru) | 2010-11-30 | 2018-08-21 | Чугаи Сейяку Кабусики Кайся | Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул |
| SI2780368T1 (en) * | 2011-11-14 | 2018-04-30 | Regeneron Pharmaceuticals, Inc. | INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| TW201823460A (zh) | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| AU2013306700B2 (en) | 2012-08-24 | 2019-05-02 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIb-specific Fc region variant |
| EP2889376A4 (en) | 2012-08-24 | 2016-11-02 | Chugai Pharmaceutical Co Ltd | ANTIBODIES Fc SPECIFIC TO FCTRII OF MOUSE |
| RS58801B1 (sr) | 2012-09-13 | 2019-07-31 | Bristol Myers Squibb Co | Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin |
| EP2911682A4 (en) | 2012-10-24 | 2016-03-23 | Celgene Corp | METHOD FOR TREATING ANEMIA |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| DK2968503T3 (en) | 2013-03-15 | 2018-12-03 | Intrinsic Lifesciences Llc | ANTI-HEPCIDIN ANTIBODIES AND APPLICATIONS THEREOF |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| DK2981822T3 (da) | 2013-05-06 | 2020-12-07 | Scholar Rock Inc | Sammensætninger og fremgangsmåder til vækstfaktormodulation |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| CA2922113C (en) | 2013-08-23 | 2023-05-23 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
| US10323088B2 (en) | 2014-09-22 | 2019-06-18 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| CA3005158A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| CN107075518B (zh) * | 2014-11-24 | 2021-03-09 | 私募蛋白质体公司 | 用于结合生长分化因子11的核酸化合物 |
| SG11201700841QA (en) | 2014-12-19 | 2017-03-30 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| CN112142844A (zh) | 2015-02-05 | 2020-12-29 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用 |
| US20180031579A1 (en) | 2015-02-12 | 2018-02-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
| AU2016249015B2 (en) * | 2015-04-15 | 2022-03-24 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with GDF8 inhibitors |
| TWI797060B (zh) | 2015-08-04 | 2023-04-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| CN113896790A (zh) | 2015-09-15 | 2022-01-07 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途 |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| CN109071645A (zh) | 2016-01-08 | 2018-12-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| KR20230169484A (ko) | 2016-06-13 | 2023-12-15 | 스칼러 락, 인크. | 미오스타틴 억제제의 용도 및 조합 요법 |
| WO2017217525A1 (en) | 2016-06-17 | 2017-12-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| RU2766112C2 (ru) | 2016-08-05 | 2022-02-08 | Чугаи Сейяку Кабусики Кайся | Композиция для профилактики или лечения связанных с il-8 заболеваний |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| CN106770517A (zh) * | 2016-12-16 | 2017-05-31 | 青岛科技大学 | 一种检测力竭运动后小鼠骨骼肌肌肉生长抑制素含量的方法 |
| EP3558347A1 (en) | 2016-12-22 | 2019-10-30 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| US11155611B2 (en) | 2017-01-06 | 2021-10-26 | Scholar Rock, Inc. | Compositions and methods for making and using anti-myostatin antibodies |
| CN114075269A (zh) | 2017-07-06 | 2022-02-22 | 菲仕兰坎皮纳荷兰私人有限公司 | 用于制备糖蛋白的细胞培养工艺 |
| CN115925882A (zh) | 2017-12-22 | 2023-04-07 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
| WO2019129679A1 (en) * | 2017-12-29 | 2019-07-04 | F. Hoffmann-La Roche Ag | Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody |
| EA202091689A1 (ru) | 2018-01-31 | 2020-10-22 | Ридженерон Фармасьютикалз, Инк. | Система и способ определения характеристик примесей, представляющих собой варианты, отличающиеся по размеру и заряду, в продукте, представляющем собой лекарственное средство |
| TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| BR112020013426A2 (pt) | 2018-02-28 | 2020-12-01 | Regeneron Pharmaceuticals, Inc. | métodos para identificação de um vírus em uma amostra e para detecção de ácidos nucleicos virais em uma amostra de cultura de células |
| MX2020008991A (es) | 2018-03-01 | 2020-12-10 | Regeneron Pharma | Metodos para alterar la composicion corporal. |
| JP7315565B2 (ja) | 2018-03-19 | 2023-07-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | マイクロチップキャピラリー電気泳動アッセイおよび試薬 |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| CA3100035A1 (en) | 2018-08-27 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Use of raman spectroscopy in downstream purification |
| US11754569B2 (en) | 2018-08-30 | 2023-09-12 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| KR20210104744A (ko) * | 2018-12-18 | 2021-08-25 | 리제너론 파마슈티칼스 인코포레이티드 | 렙틴 수용체, gdf8 및 액티빈 a에 대한 길항제를 사용하여 체중 및 제지방 근육량을 향상시키기 위한 조성물 및 방법 |
| CN113272651B (zh) | 2019-01-16 | 2023-06-16 | 瑞泽恩制药公司 | 鉴别蛋白质中的游离巯基的方法 |
| MX2021013519A (es) | 2019-05-13 | 2021-12-10 | Regeneron Pharma | Ensayos de union de ligandos competitivos mejorados. |
| US20220323937A1 (en) | 2019-09-24 | 2022-10-13 | Regeneron Pharmaceuticals, Inc. | Systems and methods for chromatography use and regeneration |
| CA3158119A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| WO2021142269A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy |
| WO2021142331A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease |
| KR20230088853A (ko) | 2020-01-21 | 2023-06-20 | 리제너론 파마슈티칼스 인코포레이티드 | 당질화된 단백질의 전기영동을 위한 탈당질화 방법 |
| BR112023003273A2 (pt) | 2020-08-31 | 2023-05-02 | Regeneron Pharma | Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina |
| WO2022115588A1 (en) | 2020-11-25 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| AU2021401301A1 (en) | 2020-12-17 | 2023-08-03 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| US12031151B2 (en) | 2021-01-20 | 2024-07-09 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
| TW202246325A (zh) | 2021-03-03 | 2022-12-01 | 美商再生元醫藥公司 | 用於定量及修飾蛋白質黏度之系統及方法 |
| MX2023010794A (es) | 2021-03-26 | 2023-10-25 | Regeneron Pharma | Metodos y sistemas para el desarrollo de protocolos de mezcla. |
| WO2022256383A1 (en) | 2021-06-01 | 2022-12-08 | Regeneron Pharmaceuticals, Inc. | Micropchip capillary electrophoresis assays and reagents |
| AR127006A1 (es) | 2021-09-08 | 2023-12-06 | Regeneron Pharma | UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc |
| KR20240058201A (ko) | 2021-09-20 | 2024-05-03 | 리제너론 파마슈티칼스 인코포레이티드 | 항체 이질성을 제어하는 방법 |
| AU2022360838A1 (en) | 2021-10-07 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
| WO2023059803A1 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
| KR20240097864A (ko) | 2021-10-26 | 2024-06-27 | 리제너론 파마슈티칼스 인코포레이티드 | 상이한 온도에서 실험실 용수를 생성하고 실험실 용수를 분배하는 시스템 및 방법 |
| WO2023177836A1 (en) | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
| WO2024064842A1 (en) | 2022-09-21 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
| US20240198253A1 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| US20240248097A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| US20240255519A1 (en) | 2023-02-01 | 2024-08-01 | Regeneron Pharmaceuticals, Inc. | Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis |
| US20240280551A1 (en) | 2023-02-22 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| WO1994021681A1 (en) | 1993-03-19 | 1994-09-29 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| US6368597B1 (en) | 1998-05-06 | 2002-04-09 | Matamorphix, Inc. | Methods of treating diabetes |
| CN1384757A (zh) | 1999-07-20 | 2002-12-11 | 法麦克萨有限公司 | 下调gdf－8活性的方法 |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| MXPA05006521A (es) * | 2002-12-20 | 2005-08-26 | Amgen Inc | Agentes de enlace que inhiben miostatina. |
| UA85055C2 (ru) | 2003-06-02 | 2008-12-25 | Уайт | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний |
| EP1699820A2 (en) | 2003-12-31 | 2006-09-13 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
| EP3006039B1 (en) | 2004-03-02 | 2021-01-06 | Acceleron Pharma Inc. | Alk7 polypeptides for use in promoting fat loss |
| EA014112B1 (ru) * | 2004-03-23 | 2010-10-29 | Эли Лилли Энд Компани | Моноклональное антитело к миостатину и способы его применения |
| JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ | Ｃｄ２０に対するヒトモノクローナル抗体 |
| BRPI0514253A (pt) | 2004-08-12 | 2008-06-03 | Wyeth Corp | terapia de combinação para diabetes, obesidade e doenças cardiovasculares usando composições contendo inibidores de gdf-8 |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| AP2007004243A0 (en) | 2005-04-25 | 2007-12-31 | Pfizer | Antibodies to myostatin |
| ES2659114T3 (es) | 2005-08-19 | 2018-03-13 | Wyeth Llc | Anticuerpos antagonistas contra GDF-8 y usos en el tratamiento de ALS y otros trastornos asociados con GDF-8 |
| JP5052517B2 (ja) * | 2005-10-06 | 2012-10-17 | イーライ リリー アンド カンパニー | 抗ミオスタチン抗体 |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| AU2006321906C1 (en) | 2005-12-06 | 2014-01-16 | Amgen Inc. | Uses of myostatin antagonists |
| US7699146B1 (en) | 2006-04-02 | 2010-04-20 | Fox Factory, Inc. | Suspension damper having inertia valve and user adjustable pressure-relief |
| SI2374818T1 (sl) | 2006-06-02 | 2013-03-29 | Regeneron Pharmaceuticals, Inc. | Visokoafinitetna protitelesa za humani IL-6 receptor |
| EP2054434B1 (en) * | 2006-08-03 | 2017-03-15 | Myostin Therapeutics Pty Ltd | Myostatin antagonists |
| SI2066695T1 (sl) | 2006-09-05 | 2013-05-31 | Eli Lilly And Company | Protitelo proti miostatinu |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| CN100586476C (zh) * | 2006-10-13 | 2010-02-03 | 中国人民解放军第四军医大学 | 一种Myostatin特异性抗体的治疗性疫苗及其制备方法 |
| TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| AU2008324243B2 (en) | 2007-11-05 | 2012-03-08 | Novartis Ag | 4-benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis |
| TWI784538B (zh) | 2008-08-14 | 2022-11-21 | 美商艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| UY32341A (es) * | 2008-12-19 | 2010-07-30 | Glaxo Group Ltd | Proteínas de unión antígeno novedosas |
| CN104725512A (zh) | 2009-04-27 | 2015-06-24 | 诺华股份有限公司 | 增加肌肉生长的组合物和方法 |
| PL2975051T3 (pl) | 2009-06-26 | 2021-09-20 | Regeneron Pharmaceuticals, Inc. | Wyizolowane z łatwością dwuswoiste przeciwciała o formacie natywnej immunoglobuliny |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| SI2780368T1 (en) | 2011-11-14 | 2018-04-30 | Regeneron Pharmaceuticals, Inc. | INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
-
2011
- 2011-05-17 JO JOP/2011/0164A patent/JO3340B1/ar active
- 2011-05-24 AR ARP110101772A patent/AR081221A1/es active IP Right Grant
- 2011-05-25 WO PCT/US2011/037837 patent/WO2011150008A1/en active Application Filing
- 2011-05-25 PL PL11726005T patent/PL2576618T3/pl unknown
- 2011-05-25 PT PT117260059T patent/PT2576618T/pt unknown
- 2011-05-25 AU AU2011258342A patent/AU2011258342B2/en active Active
- 2011-05-25 KR KR1020127033587A patent/KR101859911B1/ko active IP Right Grant
- 2011-05-25 NZ NZ603529A patent/NZ603529A/en unknown
- 2011-05-25 JP JP2013512186A patent/JP5896993B2/ja active Active
- 2011-05-25 PE PE2012002209A patent/PE20130226A1/es active IP Right Grant
- 2011-05-25 TW TW100118221A patent/TWI602917B/zh active
- 2011-05-25 CA CA2800581A patent/CA2800581C/en active Active
- 2011-05-25 HU HUE11726005A patent/HUE037140T2/hu unknown
- 2011-05-25 RS RS20170931A patent/RS56368B1/sr unknown
- 2011-05-25 MX MX2015005551A patent/MX357145B/es unknown
- 2011-05-25 UY UY0001033407A patent/UY33407A/es unknown
- 2011-05-25 LT LTEP11726005.9T patent/LT2576618T/lt unknown
- 2011-05-25 BR BR112012029986-7A patent/BR112012029986B1/pt active IP Right Grant
- 2011-05-25 SI SI201131297T patent/SI2576618T1/sl unknown
- 2011-05-25 RU RU2012156938/10A patent/RU2567805C2/ru active
- 2011-05-25 DK DK11726005.9T patent/DK2576618T3/en active
- 2011-05-25 EP EP11726005.9A patent/EP2576618B1/en active Active
- 2011-05-25 MX MX2012013369A patent/MX2012013369A/es active IP Right Grant
- 2011-05-25 US US13/115,170 patent/US8840894B2/en active Active
- 2011-05-25 TW TW105109351A patent/TW201701903A/zh unknown
- 2011-05-25 SG SG10201504092TA patent/SG10201504092TA/en unknown
- 2011-05-25 ES ES11726005.9T patent/ES2647389T3/es active Active
- 2011-05-25 RU RU2015143242A patent/RU2710156C2/ru active
- 2011-05-25 SG SG2012081964A patent/SG185455A1/en unknown
- 2011-05-25 MY MYPI2012004862A patent/MY157109A/en unknown
- 2011-05-25 CN CN201180025908.2A patent/CN102933602B/zh active Active
- 2011-05-25 NO NO11726005A patent/NO2576618T3/no unknown
-
2012
- 2012-11-12 IL IL223003A patent/IL223003A/en active IP Right Grant
- 2012-11-13 CR CR20120577A patent/CR20120577A/es unknown
- 2012-11-13 ZA ZA2012/08525A patent/ZA201208525B/en unknown
- 2012-11-14 NI NI201200171A patent/NI201200171A/es unknown
- 2012-11-20 DO DO2012000295A patent/DOP2012000295A/es unknown
- 2012-11-23 GT GT201200318A patent/GT201200318A/es unknown
- 2012-11-23 TN TNP2012000555A patent/TN2012000555A1/en unknown
- 2012-11-23 CL CL2012003283A patent/CL2012003283A1/es unknown
- 2012-11-26 EC ECSP12012309 patent/ECSP12012309A/es unknown
- 2012-12-26 CO CO12233131A patent/CO6620013A2/es unknown
-
2014
- 2014-08-18 US US14/462,085 patent/US9260515B2/en active Active
-
2015
- 2015-12-18 US US14/974,147 patent/US9890212B2/en active Active
-
2017
- 2017-10-05 HR HRP20171499TT patent/HRP20171499T1/hr unknown
- 2017-10-11 CY CY20171101065T patent/CY1119445T1/el unknown
-
2018
- 2018-01-02 US US15/860,200 patent/US20190023777A1/en not_active Abandoned
-
2022
- 2022-10-11 US US18/045,588 patent/US20240067712A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ603529A (en) | Antibodies to human gdf8 | |
| NZ600512A (en) | Neutralizing prolactin receptor antibodies and their therapeutic use | |
| RS53157B (en) | SCLEROSTINE ANTIBODIES | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| NZ608660A (en) | Anti-cd48 antibodies and uses thereof | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| NZ714313A (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| NZ714516A (en) | Human antibodies to clostridium difficile toxins | |
| RS52592B (en) | ANTI-HEPCIDINE ANTIBODIES AND THEIR USE | |
| RS53661B1 (en) | HIGH AFINITY ANTIBODY ANTIBODIES TO THE HUMAN NERVOUS FACTOR OF GROWTH | |
| NZ603607A (en) | Cgrp antibodies | |
| NZ740221A (en) | St2l antagonists and methods of use | |
| PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
| IL309975A (en) | Antibodies against C5 and their uses | |
| NZ595011A (en) | Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases | |
| EA035160B9 (ru) | Антитела к st2 и их применение | |
| NZ609619A (en) | Novel egfr-binding molecules and immunoconjugates thereof | |
| NZ598202A (en) | High affinity human antibodies to human angiopoietin-2 | |
| MX2011008843A (es) | Anticuerpos humanizados que se unen a cd19 y sus usos. | |
| RS54685B1 (en) | ANTI-N3pGlu AMILOID BETA PEPTID ANTIBODIES AND THEIR USES | |
| NZ590863A (en) | Anti-hepcidin-25 selective antibodies and uses thereof | |
| EP2604280A3 (en) | Compositions and methods for inhibiting PDGFRBETA and VEGF-A | |
| NZ583605A (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
| EP2392597A3 (en) | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use | |
| NZ623347A (en) | Novel anti-dr5 antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 25 MAY 2018 BY WATERMARK PATENT AND TRADE MARKS ATTORNEYS Effective date: 20151105 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAY 2019 BY ANAQUA SERVICES Effective date: 20180419 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAY 2020 BY ANAQUA SERVICES Effective date: 20190418 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAY 2021 BY ANAQUA SERVICES Effective date: 20200424 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAY 2022 BY ANAQUA SERVICES Effective date: 20210421 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAY 2023 BY ANAQUA SERVICES Effective date: 20220423 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAY 2024 BY ANAQUA SERVICES Effective date: 20230420 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAY 2025 BY ANAQUA SERVICES Effective date: 20240418 |